1. National Institutes of Health consensus development conference statement. Gynecol Oncol 55:S4-S14, 1994.

2. Vergote I, De Brabanter J, Fyles A, et al: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357(9251):176—182, 2001.

3. Winter-Roach B, Hooper L, Kitchener H: Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13(4):395-404, 2003.

4. Bertelsen K, Holund B, Andersen JE, et al: Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer 3(4):211-218, 1993.

5. Hreshchyshyn MM, Park RC, Blessing JA, et al: The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol 138(2):139-145, 1980.

6. Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322(15):1021-1027, 1990.

7. Bolis G, Colombo N, Pecorelli S, et al; (GICOG: Gruppo I nterregionale Collaborativo in G inecologia): Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 6(9):887-893, 1995.

8. Trope C, Kaern J, Hogberg T, et al: Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 11(3):281-288, 2000.

9. Trimbos JB, Vergote I, Bolis G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95(2):113-125, 2003.

10. Ahmed FY, Wiltshaw E, A'Hern RP, et al: Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14(11):2968-2975, 1996.

11. Buchsbaum HJ, Brady MF, Delgado G, et al: Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 169(3):226-232, 1989.

12. Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 250(22):3072-3076, 1983.

13. Leblanc E, Querleu D, Narducci F, et al: Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 94(3):624-649, 2004.

14. Colombo N, Guthrie D, Chiari S, et al: International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95(2):125-132, 2003.

15. Kolomainen DF, A'Hern R, Coxon FY, et al: Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol 21(16):3113-3118, 2003.

16. Elit L, Chambers A, Fyles A, et al: Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 101(9):1926-1935, 2004.

17. Le T, Adolph A, Krepart GV, et al: The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85(2):351-355, 2002.

18. Vergote IB, Vergote-De Vos LN, Abeler VM, et al: Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69(3):741-749, 1992.

19. Chiara S, Conte P, Franzone P, et al: High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 17(1):72-76, 1994.

20. Kojs Z, Glinski B, Reinfuss M, et al: Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer [in French]. Cancer Radiother 5(1):5-11, 2001.

21. Winter-Roach B, Hooper L, Kitchener H: Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13(4):395^04, 2003.

22. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carbopla-tin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200, 2003.

23. ICON Collaborators. International Collaborative Ovarian Neoplasm Study: ICON2: randomized trial of single-agent carbopla-tin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 352(9140):1571-1576, 1998.

24. Ozols RF: Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 26(1 Suppl 2):84-89, 1999.

25. Bamias A, Papadimitriou C, Efstathiou E, et al: Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer 6:228, 2006.

26. Chi DS, Waltzman RJ, Barakat RR, et al: Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma. Eur J Gynaecol Oncol 20(4):277-280, 1999.

27. Rubin SC, Wong GY, Curtin JP, et al: Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 82(1):143-147, 1993.

28. Shimada M, Kigawa J, Kanamori Y, et al: Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 15(4):601-605, 2005.

29. Bell J, Brady MF, Young RC, et al; Gynecologic Oncology Group: Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102(3):432-439, 2006.

30. Tumors of the ovary: neoplasms derived from celomic epithelium. In Morrow CP, Curtin JP (eds): Synopsis of Gynecologic Oncology. Philadelphia: Churchill Livingstone, 1975, p 249.

31. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11):2584-2589, 2000.

32. O'Brien ME, Schofield JB, Tan S, et al: Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 49(2):250-254, 1993.

33. Kennedy AW, Biscotti CV, Hart WR, et al: Ovarian clear cell adenocarcinoma. Gynecol Oncol 32(3):342-349, 1989.

34. Crozier MA, Copeland LJ, Silva EG, et al: Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 35(2):199-203, 1989.

35. Mizuno M, Kikkawa F, Shibata K, et al: Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 94(2):138-143, 1993.

36. Ho CM, Huang YJ, Chen TC, et al: Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94(1):197-203, 2004.

37. Takano M, Kikuchi Y, Yaegashi N, et al: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 16(6):1301-1306, 2006.

38. Malmstrom H, Simonsen E, Westberg R: A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 52(1):20-25, 1994.

39. Topuz E, Eralp Y, Saip P, et al: The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mito-xantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma. Eur J Gynaecol Oncol 22(1):70-73, 2001.

40. Fujiwara K, Sakuragi N, Suzuki S, et al: First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 90(3):637-643, 2003.

41. McGuire WP: Current aspects of adjuvant therapy of early stage ovarian cancer. Zentralbl Gynakol 120(3):93-97, 1998.

42. Skirnisdottir I, Seidal T, Sorbe B: A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 14(2):259-270, 2004.

43. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. J Epidemiol Biostat 6:107-138, 2001.

44. Omura GA, Morrow CP, Blessing JA, et al: A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51:783, 1983.

45. Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17:1061-1070, 1999.

46. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409^22, 1999.

47. Omura G, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 57:1725, 1986.

48. McGuire W, Ozols RF: Chemotherapy of advanced ovarian cancer [published erratum appears in Semin Oncol 25(6):707]. Semin Oncol 25:340, 1998.

49. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 7:457, 1989.

50. Fanning J, Bennett TZ, Hilgers RD: Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclo-

phosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80:954, 1992.

51. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group. Cochrane Database Syst CD001418, Rev 2000.

52. Aabo K, Adams M, Adnitt P, et al: Chemotherapy in advanced ovarian cancer: four systematic metastatic disease-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group. Br J Cancer 78:1479, 1998.

53. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084, 2000.

54. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carbopla-tin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194, 2003.

55. Du Bois A, Luck HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320, 2003.

56. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748, 1992.

57. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18, 1994.

58. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 12:1748, 1994.

59. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1, 1996.

60. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699, 2000.

61. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18:106, 2000.

62. International Collaborative Ovarian Neoplasm (ICON) group: Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubi-cin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505, 2002.

63. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654, 1994.

64. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682, 2004.

65. Bookman MA, Alberts DS, Brady MF, et al: GOG182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin versus combinations with gemcitabine, PEG-liposomal doxoru-bicin, or Topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma. 2006 ASCO Annual Meeting Proceedings, J Clin Oncol 24(18S):5002, 2006.

66. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34, 2006.

67. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001, 2001.

68. Pfisterer J, Weber B, Reuss A, et al: Randomized phase III trial of Topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036, 2006.

69. Hall GD, Brown JM, Coleman RE, et al: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynecology group randomized phase III study. Br J Cancer 91:621, 2004.

70. Perez-Gracia JL, Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84:201, 2002.

71. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460, 2003.

72. Ansquer Y, Leblanc E, Clough K, et al: Neoadjuvant chemotherapy for resectable ovarian carcinoma. Cancer 91:2329-2334, 2001.

73. Vergote IB, De Wever I, Decloedt J, et al: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27:31, 2000.

74. Schwartz PE, Rutherford TJ, Chambers JT, et al: Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol; 72:93, 1999.

75. Kuhn W, Rutke S, Spathe K, et al: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92:2585, 2001.

76. Mazzeo F, Berliere M, Kerger J, et al: Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90:163, 2003.

Management of Recurrent Ovarian Cancer: Chemotherapy and Clinical Trials

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment